Search

Your search keyword '"Mascola, John"' showing total 2,071 results

Search Constraints

Start Over You searched for: Author "Mascola, John" Remove constraint Author: "Mascola, John"
2,071 results on '"Mascola, John"'

Search Results

1. Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition

2. Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials

3. Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability

4. Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial

6. Cholesterol reduction by immunization with a PCSK9 mimic

7. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

8. Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site

9. Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery

10. Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections

11. First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody

12. Frequency-potency analysis of IgG+ memory B cells delineates neutralizing antibody responses at single-cell resolution

13. Long trimer-immunization interval and appropriate adjuvant reduce immune responses to the soluble HIV-1-envelope trimer base

14. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

15. Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial

16. Risk of COVID-19 after natural infection or vaccination

17. Soluble prefusion-closed HIV-envelope trimers with glycan-covered bases

18. Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition

20. Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants

21. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

22. Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses

23. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

24. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial

25. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

26. Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses

28. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope

29. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial

30. Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial

32. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

33. A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination

34. Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life

35. Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones

36. A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques

37. Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies

38. Antibodies targeting the fusion peptide on the HIV envelope provide protection to rhesus macaques against mucosal SHIV challenge

39. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

40. Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody

41. Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.

42. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

43. Quadrivalent influenza nanoparticle vaccines induce broad protection

44. Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination

45. Infusion reactions after receiving the broadly neutralizing antibody VRC01 or placebo to reduce HIV-1 acquisition: Results from the phase 2b Antibody Mediated Prevention (AMP) randomized trials

46. Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials

47. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein elicits antibodies targeting a membrane-proximal epitope

48. Risk of COVID-19 after natural infection or vaccination

49. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

50. Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1–4

Catalog

Books, media, physical & digital resources